Bank Of Montreal Zai Lab LTD Transaction History

Bank Of Montreal

$214 Billion
Q3 2024

A detailed history of Bank Of Montreal transactions in Zai Lab LTD stock. As of the latest transaction made, Bank Of Montreal holds 13,900 shares of ZLAB stock, worth $364,597. This represents 0.0% of its overall portfolio holdings.

Number of Shares

13,900

Previous 13,900 -0.0%

Holding current value

$364,597

Previous $240,000 39.58%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$15.95 - $26.8 $31,724 - $53,305	-1,989 Reduced 12.52%	13,900 $222,000
Q4 2023 Feb 08, 2024	SELL	$22.97 - $30.58 $288,365 - $383,901	-12,554 Reduced 44.14%	15,889 $434,000
Q3 2023 Nov 01, 2023	SELL	$22.72 - $31.49 $205,775 - $285,204	-9,057 Reduced 24.15%	28,443 $691,000
Q2 2023 Aug 02, 2023	SELL	$25.3 - $39.67 $29,221 - $45,818	-1,155 Reduced 2.99%	37,500 $1.04 Million
Q1 2023 Jun 13, 2024	BUY	$30.21 - $48.1 $747,848 - $1.19 Million	24,755 Added 178.09%	38,655 $1.29 Million
Q4 2022 Feb 01, 2023	SELL	$22.28 - $38.71 $4.41 Million - $7.66 Million	-197,845 Reduced 83.66%	38,655 $1.19 Million
Q3 2022 Nov 10, 2022	BUY	$34.2 - $51.69 $7.61 Million - $11.5 Million	222,600 Added 1601.44%	236,500 $11.7 Million
Q1 2022 May 12, 2022	SELL	$27.77 - $64.4 $1,610 - $3,735	-58 Reduced 0.42%	13,900 $638,000
Q4 2021 Feb 11, 2022	SELL	$54.9 - $105.21 $2.54 Million - $4.87 Million	-46,293 Reduced 76.83%	13,958 $948,000
Q3 2021 Nov 12, 2021	BUY	$105.0 - $178.37 $2.8 Million - $4.76 Million	26,701 Added 79.59%	60,251 $6.45 Million
Q2 2021 Aug 12, 2021	BUY	$125.11 - $180.0 $4.2 Million - $6.04 Million	33,550 New	33,550 $5.97 Million

Others Institutions Holding ZLAB

# of Institutions

121

Shares Held

46.7M

Call Options Held

223K

Put Options Held

588K

View Full List

About Zai Lab Ltd

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $2.57B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

More about ZLAB

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of Montreal , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of Montreal with notifications on news.

Account